Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouche, P.
Right arrow Articles by Cathala, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouche, P.
Right arrow Articles by Cathala, H. P.
NEUROLOGY 1979;29:739
© 1979 American Academy of Neurology

Perhexiline maleate and peripheral neuropathy

P. Bouche, M-G. Bousser, M. A. Peytour and H. P. Cathala

Service d'Explorations Fonctionnelles en Neurologie, et Clinique des Maladies du Systeme Nerveux, Hôpital de la Salpetriere, Paris, France.

Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris. In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder. Improvement was noted with cessation of therapy. In a few cases the presence of active denervation signified a poor prognosis, with only slight improvement. The underlying mechanism causing the neuropathy is not yet fully known, although some evidence indicates that it may be a lipid storage process.




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley
Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. Lee, J. Horowitz, and M. Frenneaux
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment
Eur. Heart J., April 2, 2004; 25(8): 634 - 641.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by AAN Enterprises, Inc.